Canada markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2900+0.1300 (+3.13%)
At close: 04:00PM EST
4.4700 +0.18 (+4.20%)
After hours: 07:23PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close4.1600
Open4.1200
Bid4.2700 x 1300
Ask4.5100 x 4000
Day's Range4.1000 - 4.3800
52 Week Range3.6700 - 10.0500
Volume947,277
Avg. Volume1,304,536
Market Cap279.919M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb. 22, 2022 - Feb. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
  • Zacks

    CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors

    The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.

  • GlobeNewswire

    CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that on January 18, 2022, the Company granted four new employees options to purchase a total of 127,000 shares of the Company’s common stock at an exercise price per share equal to $3.83, which was the closing trading price on January 18, 2022, the date of the grant. The stock options were granted pursuant to the C

  • GlobeNewswire

    CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

    - CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic -SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-